

Claims

1. Use of the Polypodium extracts for the manufacture of a pharmaceutical composition for the treatment of fibrotic diseases, such as, scleroderma, pulmonary fibrosis, atherosclerosis, bone marrow fibrosis, kidney fibrosis, cardiac fibrosis, Dupuytren's diseases, Peyronie's disease.
2. Use of Polypodium extract according to claim 1, characterized by said extracts reduce Transforming Growth Factor-beta (TGF- β) expression.
3. Use of the Polypodium extracts according to any of claim 1-2, characterized by said extracts, at least, reduce penis incurvature, reduce penis plaques, reduce coitus pain or produce an psychological improvement, in patients who suffer Peyronie's disease.
4. Use of the Polypodium extracts according to any of claims 1-3 wherein the pharmaceutical composition comprises an Polypodium extract which is obtainable by extraction using an solvent having a dielectric constant more than 20.
5. Use of Polypodium extracts according to claim 4 wherein the pharmaceutical composition comprises an extract, which is obtainable by extraction with means for dissolving water-soluble compounds.
6. Use according to any of preceding claims wherein the extracts are obtained from rhizomes.
7. Use according to claim 6 wherein extract are obtained from Polypodium leucotomos (Poiret).

Application No.: New
Attorney Docket No.: PRT 3011

8. Use according any of preceding claims characterized by the extracts comprises at least lactic acid, fumaric acid, quinic acid, citric acid or malic acid.
9. Use according to any of preceding claims characterized in that the pharmaceutical composition is orally admistrated.